IMPACT BIOMEDICAL INC. (IBO) AI Dilution Summary

Cash was $10,000 at the last reported balance-sheet date of 2026-06-30, and estimated cash was also $10,000 as of 2026-06-30. The filings describe the company funding its operations through advances from its majority holder, DSS, Inc. These advances carry no interest, are unsecured and are due on demand. The main share event described in the filings is the proposed merger with Zoar Limited.